1185 Avenue of the Americas
Suite 249
New York, NY 10036
United States
973 242 0005
https://www.petrospharma.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 21
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. John David Shulman | Executive Chairman of the Board | N/A | N/A | 1963 |
Mr. Fady Boctor M.B.A. | President & Chief Commercial Officer | 681.97k | N/A | 1978 |
Mr. Mitchell S. Arnold M.B.A. | VP of Finance & Chief Accounting Officer | 465.68k | N/A | 1964 |
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.
Petros Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.